Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Ouro, backed by GSK, joins hunt to bring bispecifics to autoimmune disease
Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...
Independence Blue Cross to exclude coverage for some drugs that get accelerated FDA approval
Independence Blue Cross has instituted an 18-month benefit exclusion on certain drugs that receive accelerated approval from ...
Biogen Inc. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a two-day winning streak.
Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?
We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...
Biogen Inc. stock outperforms competitors despite losses on the day
This was the stock's second consecutive day of losses.
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer
Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first ...
Biogen Holds On, But Growth Slips Through Its Fingers
Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.
PharmiWeb4h
Biogen Appoints Adam Feire as Head of Business Development and External Innovation
Biogen Inc. (Nasdaq: BIIB) – today announced the appointment of Adam Feire, Ph.D., as Head of Business Development and External Innovation. Mr. Feire reports to Adam Keeney, Ph.D., Executive Vice ...
Could Alzheimer’s treatment drugs be the next big investor opportunity after obesity pills?
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...